drugset / Trial / NCT07623798
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)
Timeline
- Start
- 2026-06-11
- Primary completion
- 2029-05-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bortezomib | Small molecule | — | — |
| Comparator | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | IBI3003 | Unknown | — | — |
| Comparator | Pomalidomide | Other / unclassified | 4 mg | Oral |
| Comparator | Selinexor | Other / unclassified | 100 mg | Oral |